Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States
NEW YORK , May 7, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Nuvation Bio Inc. (NYSE: NUVB) on behalf of the company's shareholders. The investigation seeks to...
NEW YORK , May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first...
Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...
Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...
Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...
Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases
 Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients
NEW YORK , April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will...